Organon & (OGN) Stock: Buy, Sell, or Hold?
OGN - Organon & Co.
$13.82
-0.02 (-0.14%)
▼
5d:
+0.58%
30d:
+0.73%
90d:
+1.92%
HOLD
MODERATE Confidence
Analysis Updated: Nov 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
5d
Get Alerted When OGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OGN trades at premium valuation expecting 8.6% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: OGN trades at premium valuation expecting 8.6% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.03
Based on 5.1% avg growth
INTRINSIC VALUE TODAY
$8.71
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OGN is currently trading at $13.82, which is considered extended relative to its 30-day fair value range of $13.72 to $13.79. From a valuation perspective, the stock is trading at a premium (Forward PE: 3.8) compared to its historical average (3.0). At these levels, the market is pricing in 8.6% annual earnings growth.
Technical Outlook: Technically, OGN is in a strong uptrend. The price is currently testing key support at $13.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $10.33. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OGN is in a strong uptrend. The price is currently testing key support at $13.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 59/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $10.33. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.72 -
$13.79
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
44.8%
Protect Your Profits
Holding OGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (59/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 25.2% above Wall St target ($10.33)
- BULLISH: Expecting earnings turnaround to 8.6% growth with -1.7% revenue growth
- NEUTRAL: Bottoming setup forming (59/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$13.72 -
$13.79
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$13.74
Resistance Level
$13.85
Current Trend
Strong Uptrend
Technical data as of
Nov 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.79
Wall Street Target
$10.33
(-25.2%)
Revenue Growth (YoY)
-1.7%
Earnings Growth (YoY)
-1.6%
Profit Margin
3.5%
Valuation Premium vs History
+8.6% premium
PE vs Historical
3.8 vs 3.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.6%
(market-implied from PE analysis)
1-Year Target
$15.01
(+9%)
2-Year Target
$16.30
(+18%)
3-Year Target
$17.70
(+28%)
3-Yr Target (if PE normalizes)
(PE: 4→3)
PE COMPRESSION
$14.02
(+1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 6.2%)
$86.66
(+527%)
Base:
(SPY PE: 3.8, Growth: 6.2%)
$16.53
(+20%)
Bear:
(PE: 3.0, Growth: 6.2%)
$13.09
(-5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (4x PE) as earnings recover.
Trailing PE: 17.74 | Current EPS (TTM): $0.78
Bull Case
$30.45
(+120%)
Analyst growth 100.0%, PE expands to 19.5
Base Case
$27.68
(+100%)
Market implied 100.0%, PE stable at 17.7
Bear Case
$9.41
(-32%)
Severe decline -20.0%, PE contracts to 15.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: November 03, 2026 1:54 AM ET
Data refreshes hourly during market hours. Next update: 2:54 AM
Data refreshes hourly during market hours. Next update: 2:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
29 analysts |
$283 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$171 | 51 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1404 | 29 SELL |
|
MRK
Merck & Company Inc |
BUY
28 analysts |
$160 | 55 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$264 | 35 SELL |
Advanced OGN Option Strategies
Professional options setups generated by AI based on today's OGN price and gamma walls.
